Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rapport Therapeutics (NASDAQ:RAPP) from a sell rating to a hold rating in a report released on Sunday morning.

Other equities analysts have also issued research reports about the company. Truist Financial started coverage on Rapport Therapeutics in a research note on Tuesday, September 16th. They set a “buy” rating and a $44.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and set a $47.00 price objective on shares of Rapport Therapeutics in a research report on Monday, December 8th. The Goldman Sachs Group upgraded shares of Rapport Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th. Finally, HC Wainwright boosted their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.80.

Rapport Therapeutics Stock Performance

RAPP stock opened at $30.76 on Friday. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $42.27. The company has a market capitalization of $1.47 billion, a PE ratio of -11.35 and a beta of 1.63. The company’s 50-day simple moving average is $27.15 and its 200 day simple moving average is $20.52.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06. On average, analysts forecast that Rapport Therapeutics will post -3.65 EPS for the current year.

Insider Transactions at Rapport Therapeutics

In related news, insider David Bredt sold 8,500 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $30.02, for a total value of $255,170.00. Following the completion of the transaction, the insider owned 392,642 shares in the company, valued at $11,787,112.84. This trade represents a 2.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Abraham Ceesay sold 5,833 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $25.81, for a total transaction of $150,549.73. Following the transaction, the chief executive officer directly owned 579,579 shares of the company’s stock, valued at $14,958,933.99. The trade was a 1.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 47,332 shares of company stock valued at $1,245,267 in the last three months. Company insiders own 13.57% of the company’s stock.

Institutional Trading of Rapport Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL acquired a new position in Rapport Therapeutics during the 3rd quarter worth about $331,000. Maven Securities LTD bought a new position in shares of Rapport Therapeutics during the third quarter worth about $594,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Rapport Therapeutics in the third quarter worth approximately $143,000. Vestal Point Capital LP acquired a new position in shares of Rapport Therapeutics in the third quarter worth approximately $28,215,000. Finally, Polar Capital Holdings Plc bought a new stake in Rapport Therapeutics in the third quarter valued at approximately $27,887,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.